Former Bachelorette star Katie Thurston is sharing a major update on her cancer journey after having to put her treatments on ...

AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase ...

When combined with clinically validated growth factor serums, microchanneling can enhance skin rejuvenation, effectively ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 11.17%, which has investors questioning if this is right time to buy.

Adding nivolumab to neoadjuvant chemotherapy significantly improves response rates in high-risk early-stage ER+/HER2− breast ...

Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.